The pharmaceutical company AstraZeneca announced today that its vaccine against it Covid-19, Vaxzevria, was approved by the European Union Regulatory Authority (Coreper) as the third boost.
The vaccine can now be used as a booster, after vaccination with two doses of Vaxzevria or by people who have previously been vaccinated with an mRNA vaccine, such as the Pfizer / BioNTech and Moderna vaccines.
"Ensuring a longer duration of immunoprotection is key to the long-term management of Covid-19 "In general, booster doses can counteract the weakening of protection over time that has been identified with all major vaccination regimens to date," said Mene Pangalos, executive vice president of biopharmaceutical research and development at AstraZeneca.
The European Medicines Agency has approved the use of Vaxzevria as a booster dose a few weeks after the European regulator approved the use of the Pfizer-BioNTech Comirnaty vaccine as a booster dose for adults who have completed the basic vaccine regimen.
Vaccine pharmaceutical companies have announced that the largest volume of vaccines this year will be booster doses or the basic vaccination regimen for children as it receives worldwide approval.
The decision of the European regulatory authority must be formally ratified by the European Commission.
Source: RES-EAP